There are at least 4 possible reasons why some people with COVID have little or no symptoms.
1) A rapid immune response that conquers the virus 2) Pre-existing cross reactive immunity 3) Genetic factors 4) Low viral load at time of infection
We have emerging data for each. 👇
1) Rapid immune response: This paper from Karolinska just out in @CellCellPress shows asymptomatic and mildly symptomatic patients have high SARS CoV-2 specific cytotoxic T cell responses. cell.com/cell/pdf/S0092…
2) Cross reactive immunity:
Many studies show presence of cross reactive T cells presumably from prior corona viral infections. They may not prevent COVID but can attenuate the severity of the disease. I think this is one reason India has less mortality. @nramind
3) Genetic factors: Lots to learn. But from ABO group to ACE polymorphisms studies are coming out on genetic susceptibility. An interesting facotr associated with severe disease is TLR-7 mutations on X chromosome: also explains milder disease in women. jamanetwork.com/journals/jama/…
4) Viral dose at exposure. This is NOT the same as viral dose measured in asymptomatic vs symptomatic people. It’s the initial exposure dose that’s almost impossible to measure. But we have circumstantial evidence. @jeremyphoward@DrSidMukherjee@AliNouriPhD@DrEricDing@ASlavitt
Understanding why some people have completely asymptomatic disease and some get life threatening disease is critical. I’m amazed we know so much in such a short time. But this is nothing compared to what we will know in 6 months to a year. @Rfonsi1
I study cancers of the immune system. My job is to kill the cells that help us fight infection. The same cells that make antibodies. To kill them, we have to understand them. And the one think I’ve learnt is that it’s extraordinarily hard to get rid of them: Normal or cancerous.
Which is why I have hope that natural infection or vaccines will be effective. Maybe not in preventing a recurrent infection. But certainly attenuating the disease and making future versions more like regular flu or hopefully milder.
What is happening in India where disease severity and mortality appear much lower, is related to what I have posted as the 4 factors. And the main one I suspect of the 4 to be playing a role in India is cross reactive prior immunity.
In the year 2000, a few of us attended an angiogenesis meeting in Boston. We were there to discuss thalidomide
But a side meeting that evening led to trial that went on to get Velcade FDA approved for myeloma. @NEJM
Story in thread.
Velcade (bortezomib) was first introduced to cancer research by the name PS-341.
It was a novel proteasome inhibitor developed by Julian Adams and colleagues a a potential anti cancer agent. @CR_AACR @AACR aacrjournals.org/cancerres/arti…
The ubiquitin-proteasome garbage disposal pathway in cells is a Nobel prize winning discovery.
Proteins that need to be degraded are tagged with ubiquitin tails. Tagged proteins are degraded by the proteasome complex. (This review has details )
The fascinating story of Thalidomide: how this most notorious drug on the planet, banned in the 1960s, made an incredible comeback and revolutionized the treatment of myeloma.
I will also highlight one person whose role is not recognized: Without Dr. Leif Bergsagel there will be no thalidomide for myeloma.
Read on #MedTwitter
The thalidomide story has many takeaways and lessons.
It shows drug development from bedside to bench and back to bedside.
It shows the power and impact of astute clinicians
It shows the power of investigator courage
The role of serendipity
But let’s start at the very beginning.
Thalidomide was synthesized in 1954, and then developed as a sleeping pill by the German company Chemie Grünenthal in the 1950s.
At the time the only sedatives available were barbiturates which had risks of intentional or accidental overdose.
Because thalidomide was felt to be a drug that cannot cause death due to overdose it was marketed as one of the safest sedatives.
By 1961, it was sold in over 40 countries as a sleeping. It was also tragically used to control morning sickness of early pregnancy.
AQUILA trial for high risk smoldering myeloma published in @NEJM today.
@thanosdimop
Personally for me, it is a huge milestone along 25 years of work that started in 1998. #ASH24 #ASH24VR
This story below may help those interested in a clinical trialist career. 1/
In 1998, as a fellow @MayoClinic I was keen to determine if early intervention delayed progression and improved survival in SMM. #ASH24
In 1999, with the help of Tom Witzig, I led a small phase II trial of thalidomide for SMM. @LeukemiaJnl 2/
I was then so fortunate to examine the natural history of SMM, with the legendary Bob Kyle. Honored to be last author on @NEJM paper that also provided data that most progressions occur in the first 5 years of diagnosis.
The start of the concept of high risk vs low risk SMM. 3/
FDA approval doesn’t necessarily mean standard of care.
Thread.
1/
For example FDA approved Dara VMP for frontline therapy in myeloma in 2018.
Literally no one used the regimen in the US.
Literally no one felt the regimen was standard of care in the US.
Before or after approval!
Why?
FDA adjudicates a sponsors submission on whether a given drug/regimen has met the burden of proving safety and efficacy.
Standard of care in clinical practice is a different standard: judgment of risk/benefit of available alternatives, and assessment of trial design/end points.